FindTrial
Sign In

Optimizing individualized dosing regimen of vancomycin based on JPKD-vancomycin Population pharmacokinetic software and clinical application in patients of augmented renal clearance

Optimizing individualized dosing regimen of vancomycin based on JPKD-vancomycin Population pharmacokinetic software and clinical application in patients of augmented renal clearance

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016849
Enrollment
Unknown
Registered
2018-06-28
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe infection

Interventions

Intervention group:Using JPKD-vancomycin Software to design vancomycin dosing regimen
Control group:Vancomycin was administered empirically

Sponsors

Suzhou Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. CLCR>130 ml/min/1.73m2 while before vancomycin treatment; 2. Patients with severe infection were treated with vancomycin; 3. vancomycin treatment =3d; 4. determined vancomycin trough cincentration.

Exclusion criteria

Exclusion criteria: Age < 18 years; Continuous renal replacement therapy (CRRT) or hemodialysis during vancomycin use;Allergy to vancomycin or severe adverse reaction related to vancomycin; Scr increased more than 50% when compared to before vancomycin treatment; Transferred to other hospital during vancomycin treatment, incomplete data, unable to evaluate effect

Design outcomes

Primary

MeasureTime frame
Vancomycin plasma trough concentration;AUC/MIC;MRES;Clinical efficiency;—

Countries

China

Contacts

Public ContactTang Lian, Fang Jie, Lu Haodi,Shang Erning

Suzhou Hospital Affiliated to Nanjing Medical University

tanglian716@aliyun.com+86 15250491039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026